Nachrichten zur Vertex Pharmaceuticals Inc. Aktie

Believe it or not, but were not far away from being halfway through the year. Time flies when youre having…

The markets recent correction looks like a massive drop on a year-to-date chart. However, it will look far less daunting…

Resilient and growing. Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of…

Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The companys…

The United States, like all countries, has gone through its share of ups and downs -- from soaring economies to…

One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the…

Its very tempting to pile into the stocks with the strongest positive momentum of the moment -- theyve proven themselves…

Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was,…

Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over…

Uncertainty has weighed on stocks over the past several weeks, pushing the three major indexes lower -- the S&P 500…

Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. However, even…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Wolfe Research: Von Hoffnungsträger zum Sorgenkind? Wolfe Research zieht bei Vertex die Reißleine Wolfe…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Morgan Stanley: Rating und Kursziel Morgan Stanley hat das Kursziel für die Aktie von Vertex…

Boston, MA (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Leerink Partners: Aktuelle Bewertung Leerink hat das Rating für Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

These are some of the stocks posting the largest moves in premarket trading.…

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came…

Heres our initial take on Vertex Pharmaceuticals (NASDAQ: VRTX) first-quarter financial report. Key Metrics Metric Q1 2024 Q1 2025 Change vs. Expectations Total revenue $2.69 billion $2.77 billion +3% Missed Adjusted earnings…

…

Vertex (VRTX) delivered earnings and revenue surprises of -3.79% and 1.72%, respectively, for the quarter ended March 2025. Do the…

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF)…

Vertex Pharmaceuticals misses Q1 estimates, shares slip…

Any time is a great time to buy stocks -- if you pick the right stocks. Thats true even in…

The Trade Desks share price has been clobbered this year, but its prospects are bright. Vertex Pharmaceuticals impressive momentum…

Vertex Pharmaceuticals (VRTX) reachead $509.47 at the closing of the latest trading day, reflecting a +1.19% change compared to its…

Getting dizzy from the stock markets gyrations? Join the club. The major market indexes are behaving like a frantic yo-yo,…

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.…

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotechs shares closed the day nearly 3%…

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However,…

President Trump isnt a fan of Fed Chairman Jerome Powell, despite nominating Powell to replace Janet Yellen in 2017. Trump…

A "monster stock" might be one that frightens you by free-falling. Or it might alarm you with characteristics such as…

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff…

Yo-yos are fun for kids. But yo-yo stock markets arent so fun for grown-up investors. And unfortunately, theres been a…

When the stock market is as turbulent as it is these days, its easy to forget the times when things…

"May you live in interesting times." That probably isnt an ancient Chinese curse as some think. However, many investors might wish…

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire,…

Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its…

Equity markets may be struggling because of President Donald Trumps current economic policies, but that doesnt mean investors should avoid…

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex…

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year,…

Stocks are sinking the most since the COVID-19-fueled sell-off in 2020. A global trade war seems imminent. JPMorgan Chase just…

…

Which group of individuals is in the best position to spot early warning signs of economic trouble? Theres a good…

Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its…

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $492.69, signifying a -1.96% move from its prior days close.…

Vertex Pharmaceuticals (VRTX) closed at $502.55 in the latest trading session, marking a +0.45% move from the prior day.…

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to…

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close.…

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $512.52, indicating a +0.06% shift from the previous trading…

Equity markets started 2025 pretty well, but things havent been so rosy in the past couple of months. The tech-heavy…

Vertex Pharmaceuticals (VRTX) ist als Marktführer zur Behandlung von zystische Fibrose (CF) bisher stark vom Kernprodukt TRIKAFTA mit 93 %…